In the Claims:

Claims 1-20: (cancelled)

Claim 21 (currently amended): A method of administering folic acid to a subject for whom an oral contraceptive is indicated for preventing pregnancy, which comprises administering to the subject a pharmaceutical composition, wherein

the pharmaceutical composition comprises an oral contraceptive for preventing pregnancy in a subject, and folic acid in an amount sufficient to reduce the risk of <u>neural tube defects</u> eervical dysplasia or cervical earcinoma in the subject, wherein (i) subjects for whom the oral contraceptive is indicated are afflicted with <u>neural tube defects</u> eervical dysplasia or cervical earcinoma at a higher-than-normal incidence, (ii) said <u>neural tube defects</u> eervical dysplasia or cervical earcinoma results from folic acid deficiency, and (iii) the risk of <u>neural tube defects</u> eervical dysplasia or cervical earcinoma in the subject is reduced by folic acid administration.

Claim 22 (previously presented): The method of claim 21, wherein the composition comprises from about 25 μg to about 1 g of folic acid.

Claim 23 (previously presented): The method of claim 22, wherein the composition comprises about 400 μ g of folic acid.

Claim 24 (new) The method of claim 21, wherein the neural tube defects are selected from the group consisting of spina bifida and anecephaly.